Last reviewed · How we verify
EPCAM-targeted CAR-T cells
EPCAM-targeted CAR-T cells is a Biologic drug developed by Sinobioway Cell Therapy Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | EPCAM-targeted CAR-T cells |
|---|---|
| Sponsor | Sinobioway Cell Therapy Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IMC001 for Clinical Research on Advanced Digestive System Malignancies (PHASE1)
- Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART) (PHASE1)
- Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (NA)
- Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer (NA)
- A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EPCAM-targeted CAR-T cells CI brief — competitive landscape report
- EPCAM-targeted CAR-T cells updates RSS · CI watch RSS
- Sinobioway Cell Therapy Co., Ltd. portfolio CI
Frequently asked questions about EPCAM-targeted CAR-T cells
What is EPCAM-targeted CAR-T cells?
EPCAM-targeted CAR-T cells is a Biologic drug developed by Sinobioway Cell Therapy Co., Ltd..
Who makes EPCAM-targeted CAR-T cells?
EPCAM-targeted CAR-T cells is developed by Sinobioway Cell Therapy Co., Ltd. (see full Sinobioway Cell Therapy Co., Ltd. pipeline at /company/sinobioway-cell-therapy-co-ltd).
What development phase is EPCAM-targeted CAR-T cells in?
EPCAM-targeted CAR-T cells is in Phase 1.